544 related articles for article (PubMed ID: 24566409)
1. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
[TBL] [Abstract][Full Text] [Related]
2. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
3. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
[TBL] [Abstract][Full Text] [Related]
4. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
5. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study.
Minamimoto R; Nakaigawa N; Nagashima Y; Toyohara J; Ueno D; Namura K; Nakajima K; Yao M; Kubota K
Abdom Radiol (NY); 2016 Mar; 41(3):521-30. PubMed ID: 27039323
[TBL] [Abstract][Full Text] [Related]
8. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
9. Role of FDG PET-CT in recurrent renal cell carcinoma.
Kumar R; Shandal V; Shamim SA; Jeph S; Singh H; Malhotra A
Nucl Med Commun; 2010 Oct; 31(10):844-50. PubMed ID: 20661166
[TBL] [Abstract][Full Text] [Related]
10. 18F-Fluoride PET/CT for detection of bone metastasis in patients with renal cell carcinoma: a pilot study.
Sharma P; Karunanithi S; Chakraborty PS; Kumar R; Seth A; Julka PK; Bal C; Kumar R
Nucl Med Commun; 2014 Dec; 35(12):1247-53. PubMed ID: 25171438
[TBL] [Abstract][Full Text] [Related]
11. [Malignant tumor with false negative 18F-FDG PET image].
Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
[TBL] [Abstract][Full Text] [Related]
13. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic role of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography in restaging renal cell carcinoma.
Ozturk H
Minerva Urol Nefrol; 2016 Jun; 68(3):263-9. PubMed ID: 25916217
[TBL] [Abstract][Full Text] [Related]
15. Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma.
Bertagna F; Motta F; Bertoli M; Bosio G; Fisogni S; Tardanico R; Ferrari V; Antonelli A; Simeone C; Cosciani Cunico S; Giubbini R
Nucl Med Rev Cent East Eur; 2013; 16(1):3-8. PubMed ID: 23677757
[TBL] [Abstract][Full Text] [Related]
16. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
[TBL] [Abstract][Full Text] [Related]
17. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT.
Takahashi M; Kume H; Koyama K; Nakagawa T; Fujimura T; Morikawa T; Fukayama M; Homma Y; Ohtomo K; Momose T
Clin Nucl Med; 2015 Dec; 40(12):936-40. PubMed ID: 26164183
[TBL] [Abstract][Full Text] [Related]
18. Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma.
Ho CL; Chen S; Ho KM; Chan WK; Leung YL; Cheng KC; Wong KN; Cheung MK; Wong KK
Clin Nucl Med; 2012 Nov; 37(11):1075-82. PubMed ID: 22996247
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.
Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B
Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925
[TBL] [Abstract][Full Text] [Related]
20. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
Liu Y
Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
